Century Therapeutics (NASDAQ: IPSC) is a biotechnology company advancing a pipeline of induced pluripotent stem cell (iPSC)-derived cell therapies with the potential to meaningfully address autoimmune diseases, including type 1 diabetes, and cancer. The company’s therapies are derived from its iPSC cell foundry and leverage its novel immune evasion engineering technology, Allo-Evasion™. Century believes its approach to developing off-the-shelf cell therapies will expand patient access and provide advantages over existing cell therapies which will ultimately advance the course of care. Position Summary We are seeking a highly motivated and innovative co-op to support development, optimization, and fit-for-purpose qualification of flow cytometry based and molecular ddPCR assays for Phase 1 clinical studies in cell therapy, following FDA guidance for early-phase bioanalytical method development. In this role, the co-op will work closely with a small team of scientists to develop robust assays to assess clinical assets’ therapeutic performance. The student will gain hands-on experience with immune cell culture, flow cytometry, and a range of in vitro functional assays used to assess cell therapy products. These biomarker approaches will be examined through the lens of bioanalytical method industry standards. The co-op will also contribute to data analysis, interpretation, and presentation of findings to internal teams. This opportunity is ideal for a candidate who is enthusiastic about immunology, cell therapy, and translational research, and who is eager to build technical and analytical skills in a biotech environment focused on advancing innovative therapies toward the clinic.
Stand Out From the Crowd
Upload your resume and get instant feedback on how well it matches this job.
Job Type
Full-time
Career Level
Entry Level
Education Level
No Education Listed